Akebia Therapeutics (AKBA) Operating Margin (2016 - 2025)
Historic Operating Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to 7.57%.
- Akebia Therapeutics' Operating Margin rose 409800.0% to 7.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.88%, marking a year-over-year decrease of 2280900.0%. This contributed to the annual value of 31.51% for FY2024, which is 4310500.0% up from last year.
- According to the latest figures from Q3 2025, Akebia Therapeutics' Operating Margin is 7.57%, which was up 409800.0% from 22.55% recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Operating Margin registered a high of 26.97% during Q2 2022, and its lowest value of 149.95% during Q2 2021.
- For the 5-year period, Akebia Therapeutics' Operating Margin averaged around 48.28%, with its median value being 31.0% (2023).
- Examining YoY changes over the last 5 years, Akebia Therapeutics' Operating Margin showed a top increase of 2747300bps in 2021 and a maximum decrease of -573300bps in 2021.
- Over the past 5 years, Akebia Therapeutics' Operating Margin (Quarter) stood at 113.28% in 2021, then soared by 92bps to 8.73% in 2022, then soared by 88bps to 1.07% in 2023, then plummeted by -2776bps to 30.77% in 2024, then soared by 125bps to 7.57% in 2025.
- Its last three reported values are 7.57% in Q3 2025, 22.55% for Q2 2025, and 23.57% during Q1 2025.